Safety Concerns Halt Merck & Co’s Once-Weekly HIV Combination
Blow For Company’s HIV Strategy
Merck & Co. is looking to compete in the burgeoning long-acting HIV market, but a safety halt to a Phase II trial could disrupt those plans.

Merck & Co. is looking to compete in the burgeoning long-acting HIV market, but a safety halt to a Phase II trial could disrupt those plans.